The way we treat pain is changing. With the change in scheduling for codeine containing products, it is a chance for doctors and pharmacists to re-evaluate their approach to helping patients with chronic and neuropathic pain.
Prolonged high systemic drug concentrations after oral NSAID therapy may result in potentially serious adverse events such as gastrointestinal ulceration or bleeding, hypertension, and cardiovascular events, acute renal impairment, and hepatotoxicity2,3. Local, non-systemic treatment of neuropathic and arthritic pain may be a good alternative for many patients, reducing the risk of such effects, which can deliver effective analgesic concentrations at the site of inflammation while minimizing systemic concentrations. Lower systemic concentrations after topical administration would also be expected to result in a lower risk of drug– drug interactions resulting from NSAID-mediated displacement of drugs binding to plasma proteins or alterations in drug concentrations due to induction or inhibition of cytochrome P450 enzymes.
Development of transdermal formulations has been based on this approach to overcoming these significant obstacles to efficacy and compliance. Versatile™, is uniquely formulated for effective transdermal pain therapy, while having an elegant skin feel. The base does not contain any harmful, obsolete or controversial ingredients, such as parabens, petrolatum or sodium lauryl sulphate.
The unique Versatile™ cream base has been developed for superior patient satisfaction and flexibility for many therapy regimens, including pain management with multiple drugs. Versatile™ is the only cream base proven to provide simultaneous percutaneous absorption of six commonly prescribed pain drugs while remaining durable and elegant.1 Combining all medications into one non-invasive, elegant, topical formulation is a solution for many patients. With clinical trials showing significant pain relief when patients use Versatile™ compounded pain creams, Versatile™ is the ideal and optimal choice for topical pain management therapy.
Please contact the team at Fagron on 1300 789 565 or info@fagron.com.au for more information
- Wang & Black (2013). Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine and Pentoxyfylline: Comparison of Versatile Cream vs. Reference Cream, International Journal of Pharmaceutical Compounding, 17:6:November/Decemer 2013, pg.520-525
- Franckum J, Ramsay D, Das NG et al. Pluronic lecithin organogel for local delivery of anti-inflammatory drugs. International journal of pharmaceutical compounding. 2004; 8(2):p.101-105
- Barkin R. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. American journal of therapeutics. 2012. Epub ahead of print.
